RMTG
What one share of Regenerative Medical Technology Group holds
Retail – Retail Stores, NEC
Our mission is to empower physicians globally to deliver the transformative benefits of regenerative medicine—stem cell therapies, exosomes, peptides, and advanced combination protocols—to patients seeking effective, natural alternatives to traditional surgical, palliative, or symptom-management approaches.
Regenerative Medical Technology Group’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.73 |
|---|---|
| Profit | −$0.68 |
| Capex (buildings and equipment) | $0.07 |
| Free cash flow | −$0.04 |
| Cash and investments | $0.10 |
| Debt | $0.15 |
| Book value | −$2.86 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $0.01 | −$0.11 | — | −$0.00 | — | −$0.68 |
| 2018 | $0.01 | −$0.50 | $0.00 | −$0.06 | — | −$0.93 |
| 2019 | $0.01 | −$0.47 | $0.02 | −$0.09 | — | −$0.92 |
| 2020 | $0.01 | −$0.63 | $0.01 | −$0.05 | — | −$0.59 |
| 2021 | $0.04 | −$1.12 | — | −$0.86 | — | −$0.56 |
| 2022 | $0.13 | −$0.45 | $0.02 | −$0.11 | — | −$0.96 |
| 2023 | $0.19 | −$0.79 | $0.03 | −$0.06 | — | −$1.74 |
| 2024 | $0.33 | −$0.44 | $0.02 | $0.05 | — | −$2.18 |
| 2025 | $0.40 | −$0.62 | $0.05 | −$0.10 | — | −$2.74 |